Corporate Venture Strikes Again: Biocartis Lands €30 million--And A Partnership
The two deals help pave a path toward commercialization for the privately-held Swiss molecular diagnostics player.
The two deals help pave a path toward commercialization for the privately-held Swiss molecular diagnostics player.